In this Issue:
BRAF mutation: prognostic impact in advanced and recurrent CRC
Panitumumab-FOLFOX4 benefits wild-type KRAS tumours
Panitumumab-FOLFIRI active in wild-type KRAS tumours
Cetuximab-CAPIRI vs cetuximab-CAPOX: active mCRC regimens
Panitumumab: QOL benefit in KRAS wild-type tumours
Ca/Mg infusions reduce oxaliplatin-related neurotoxicity
Classify all node-negative stage II patients with ITDs as stage III?
Lymph node harvest: the more the better
CEA is a useful prognostic marker in CRC
Cost-effectiveness of capecitabine-based chemotherapy
Please login below to download this issue (PDF)